ABNewswire - Press Release Distribution Service

Tuesday, June 23, 2026

Hemophilia A Pipeline Gains Momentum: 40+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Hemophilia A Pipeline Insights 2026” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in the Hemophilia A pipeline landscape. It covers the Hemophilia A pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia A pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Hemophilia A Pipeline @ https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020

Key Takeaways from the Hemophilia A Pipeline Report

On June 15, 2026- Bayer conducted a phase 1/2 study researchers want to gather more information about safety and effectiveness of BAY 2599023 (DTX201), a drug therapy that delivers the human factor VIII gene into the human body by use of a viral vector to treat the disease. By replacing the defective gene with a healthy copy the human body may produce clotting factor on its own. Hemophilia A is a bleeding disorder in which the human body does not have enough clotting factor VIII, a protein that controls bleeding. Researcher want to find the optimal dose of BAY 2599023 (DTX201) so that the body may produce enough clotting factor on its own.
On June 12, 2026- Novo Nordisk A/S initiated a study is looking at how Mim8 works in people with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medicine that will be used to avoid bleeding episodes. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). The study will last for up to 5.5 years. The duration of the study depends on when the participant enrolled in this study.
On June 12, 2026- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. announced a phase III study is a single arm, open, multicenter clinical trial in which the previous treated severe hemophilia A patients receive recombinant human coagulation factor VIII for injection to evaluate the efficacy and safety of on-demand treatment in the event of new bleeding events. If evaluable surgical cases occur, the overall efficacy and safety of recombinant human coagulation factor VIII for injection as a replacement therapy for severe hemophilia A PTPs during the perioperative period will be evaluated.
On June 08, 2026- Hoffmann-La Roche conducted a phase III study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of NXT007 prophylaxis compared with Factor VIII (FVIII) prophylaxis in participants with severe or moderate congenital hemophilia A without inhibitors. The study will include people aged ≥12 years old with severe or moderate congenital hemophilia A without inhibitors on previous FVIII prophylaxis treatment.
DelveInsight’s Hemophilia A pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Hemophilia A treatment.
The leading Hemophilia A Companies such as Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd., Bayer, Ultragenyx Pharmaceutical, Spark Therapeutics, Octapharma, ApcinteX Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Expression Therapeutics, LLC, CSL Behring and others.
Promising Hemophilia A Pipeline Therapies such as Emicizumab, rFVIIa, aPCC, BAX 888, OBIZUR, BIIB031 (rFVIIIFc), Recombinant Human Coagulation FVIII, and others.

Stay ahead with the most recent Hemophilia A pipeline outlook with DelveInsight @ Hemophilia A Treatment Drugs

The Hemophilia A Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Hemophilia A Pipeline Report also highlights the unmet needs with respect to the Hemophilia A.

Hemophilia A Overview

Hemophilia A is an inherited bleeding disorder in which the blood does not clot normally. People with hemophilia A will bleed more than normal after an injury, surgery, or dental procedure. This disorder can be severe, moderate, or mild. In severe cases, heavy bleeding occurs after minor injury or even when there is no injury (spontaneous bleeding). Bleeding into the joints, muscles, brain, or organs can cause pain and other serious complications. In milder forms, there is no spontaneous bleeding, and the disorder might only be diagnosed after a surgery or serious injury. Hemophilia A is caused by having low levels of a protein called factor VIII. Factor VIII is needed to form blood clots. The disorder is inherited in an X-linked recessive manner and is caused by changes (mutations) in the F8 gene.

Hemophilia A Emerging Drugs Profile

AGN-193408: Allergan

Allergan is conducting a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-group (Cohort 2) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension. It is an implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix.

OCTA101: Octapharma

Octapharma is evaluating OCTA101 (a human-cl rhFVIII and recombinant human von Willebrand Factor fragment dimer) under a Phase 1/2 study, which will be a dose escalation study in adults in 5 cohorts, with the main purpose to assess the safety of subcutaneous injection of OCTA101 (in previously treated adult patients with severe hemophilia A. The study also aims to assess the pharmacokinetics (PK) characteristics, dose proportionality, and subcutaneous bioavailability of OCTA101 compared with intravenous administration of Nuwiq (Human-cl rh FVIII), in order to define the prophylactic treatment (dose and injection interval) that would result in protective trough levels of FVIII:C for future Phase 3 studies. By Data Monitoring Committee recommendation, patients enrolled in cohorts 1, 2 and 3 will proceed to 3-month prophylactic treatment to receive daily dosing of OCTA101 for 3 months.

Valoctocogene roxaparvovec: BioMarin Pharmaceuticals

Valoctocogene roxaparvovec, is an investigational gene therapy in clinical trials for the treatment of Hemophilia A and has not been determined to be safe or effective. Valoctocogene roxaparvovec is administered as a single infusion. The ongoing clinical trials will determine if the new gene will enable the body to produce factor VIII. Following infusion, clinical trial subjects are being evaluated to determine the safety profile, changes in Factor VIII activity levels, changes in factor replacement usage, changes in reported bleeds requiring factor replacement, and quality of life measures, among other endpoints.

The Hemophilia A Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Hemophilia A with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia A Treatment.
Hemophilia A Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Hemophilia A Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hemophilia A market

Explore groundbreaking therapies and clinical trials in the Hemophilia A Pipeline @ New Hemophilia A Drugs

Hemophilia A Companies

Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd., Bayer, Ultragenyx Pharmaceutical, Spark Therapeutics, Octapharma, ApcinteX Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Expression Therapeutics, LLC, CSL Behring and others.

Hemophilia A pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Molecule Type

Hemophilia A Products have been categorized under various Molecule types such as

Small molecules
Gene Therapies
Bispecific antibodies
Recombinant proteins
Fusion Proteins
Coagulants
Blood coagulation factor replacements

Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Hemophilia A Market Drivers and Barriers

Scope of the Hemophilia A Pipeline Report

Coverage- Global
Hemophilia A Companies- Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd., Bayer, Ultragenyx Pharmaceutical, Spark Therapeutics, Octapharma, ApcinteX Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Expression Therapeutics, LLC, CSL Behring and others.
Hemophilia A Pipeline Therapies- Emicizumab, rFVIIa, aPCC, BAX 888, OBIZUR, BIIB031 (rFVIIIFc), Recombinant Human Coagulation FVIII, and others.
Hemophilia A Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Hemophilia A Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Hemophilia A Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Hemophilia A Companies, Key Products and Unmet Needs

Table of Contents

Introduction
Executive Summary
Hemophilia A: Overview
Pipeline Therapeutics
Therapeutic Assessment
Hemophilia A – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Hemophilia A Collaboration Deals
Late Stage Products (Pre-registration)
Valoctocogene roxaparvovec: BioMarin Pharmaceutical
Late Stage Products (Phase III)
Giroctocogene fitelparvovec: Pfizer/ Sangamo Therapeutics
Mid Stage Products (Phase II)
Comparative Analysis
NNC0365-3769 A (Mim8): Novo Nordisk A/S
Early Stage Products (Phase I/II)
Comparative Analysis
BAX 888: Baxalta / Shire
BAY2599023: Bayer / Ultragenix Pharmaceutical
Early Stage Products (Phase I)
Gene therapy: Expression Therapeutics, LLC
Hemophilia A Key Companies
Hemophilia A Key Products
Hemophilia A- Unmet Needs
Hemophilia A- Market Drivers and Barriers
Hemophilia A- Future Perspectives and Conclusion
Hemophilia A Analyst Views
Hemophilia A Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/hemophilia-a-pipeline-insight-2020

The Diabetic Neuropathy Therapeutics Market Size (7MM) is projected to grow with a significant CAGR over the forecast period of 2026-2036

DelveInsight’s “Diabetic Neuropathy Market Insights, Epidemiology, and Market Forecast – 2036” report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the Diabetic Neuropathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover Key Insights into the Market with DelveInsight's In-Depth Report @ https://www.delveinsight.com/sample-request/diabetic-neuropathy-market

Key Takeaways from the Diabetic Neuropathy Market Report

In January 2026, Lexicon Pharmaceuticals completed its End-of-Phase 2 meeting with the US FDA for pilavapadin in Diabetic Peripheral Neuropathic Pain, with no objections to Phase III, which will involve two 12-week placebo-controlled studies of a 10 mg dose, with a change in average daily pain score as the primary endpoint.
According to DelveInsight’s estimates, the US accounts for the highest prevalent cases in 2025 and is expected to increase at a significant CAGR by 2036.
According to the International Diabetes Federation (IDF), more than 43 million adults in the United States are affected by diabetes, highlighting the substantial national disease burden and associated risk of long-term complications.
According to secondary sources, diabetic neuropathy, a common complication of diabetes, affects more than 30% of individuals with the disease, as reported by the Survey Research Group of the Japan Physicians Association.
The observed female predominance and earlier onset of Diabetic Neuropathy highlight the importance of gender-specific screening, early diagnosis, and timely intervention to prevent disease progression and long-term complications.
According to secondary sources, approximately 32% of individuals with diabetes in Italy were reported to have diabetic neuropathy, highlighting a substantial burden of neurological complications.
The leading Diabetic Neuropathic Pain Companies include Novo Nordisk, Ionis Pharmaceuticals, Pfizer, Regeneron, NeuroMetrix, and others.
Promising Diabetic Neuropathic Pain Therapies include Duloxetine, CNTX-6016, MEDI 7352, and others.

Stay ahead in the Diabetic Neuropathy Therapeutics Market with DelveInsight’s Strategic Report @ Diabetic Neuropathy Market Outlook

Diabetic Neuropathy Epidemiology Segmentation in the 7MM

Total Diagnosed Prevalent Cases of Diabetes Mellitus
Total Diagnosed Prevalent Cases of Diabetic Neuropathy
Gender-specific Diagnosed Prevalent Cases of Diabetic Neuropathy
Total Treated Cases of Diabetic Neuropathy

Download the report to understand which factors are driving Diabetic Neuropathy epidemiology trends @ Diabetic Neuropathy Prevalence

Diabetic Neuropathy Approved Therapies

Capsaicin (QUTENZA): Grünenthal (Averitas Pharma)

QUTENZA, developed by Grünenthal (through its US subsidiary Averitas Pharma), is a high-concentration (8%) topical capsaicin patch designed for the treatment of neuropathic pain, including pain associated with Diabetic Neuropathy. Capsaicin, the active component derived from chili peppers, acts as a TRPV1 receptor agonist, leading to de-functionalization of nociceptive nerve fibers and long-lasting pain relief following a single localized application.

Diabetic Neuropathy Pipeline Analysis

Suzetrigine (JOURNAVX): Vertex Pharmaceuticals

Suzetrigine, developed by Vertex Pharmaceuticals, is an oral, highly selective NaV1.8 inhibitor, targeting the voltage-gated sodium channel predominantly expressed in peripheral nociceptive neurons, reducing the initiation and transmission of pain signals without affecting central nervous system pathways. This targeted peripheral action aims to provide effective analgesia while minimizing CNS-related side effects commonly seen with traditional pain therapies.

Pilavapadin (LX9211): Lexicon Pharmaceuticals

LX9211, developed by Lexicon, is an orally administered small molecule being developed for the treatment of diabetic peripheral neuropathy. Preclinical studies demonstrated that LX9211 effectively penetrates the central nervous system and reduces pain behavior in neuropathic models without affecting opioid pathways. Discovered in a drug discovery alliance between Lexicon Pharmaceuticals and Bristol-Myers Squibb, Lexicon holds exclusive rights to its development and commercialization.

Get In-Depth Knowledge on Diabetic Neuropathy Market Trends and Forecasts with DelveInsight @ Diabetic Neuropathy Treatment Market

Diabetic Neuropathy Market Outlook

The Diabetic Neuropathy market is undergoing a gradual transformation, shifting beyond traditional symptomatic management with generic analgesics and antidepressants toward more targeted, mechanism-based therapies. The emergence of novel agents such as selective sodium channel inhibitors (e.g., Nav1.8 inhibitors) and kinase inhibitors highlights a growing focus on addressing underlying pain signaling pathways rather than broad CNS modulation. Additionally, non-systemic approaches like high-concentration capsaicin patches reflect a trend toward localized treatment with improved safety and reduced systemic side effects, enhancing patient adherence and tolerability. These innovations validate a shift toward precision-driven pain management and are reshaping the competitive landscape.

Diabetic Neuropathy Treatment Landscape

The Diabetic Neuropathy treatment landscape is evolving in line with other chronic, high-burden pain conditions where unmet need remains substantial. The United States represents the largest market, driven by high diabetes prevalence, improved diagnosis rates, strong access to advanced therapies, and increasing emphasis on opioid-sparing treatment strategies, followed by Europe and Japan. Overall, the introduction of differentiated, non-opioid therapies, expansion of pipeline assets with novel mechanisms, improving diagnosis rates, and growing awareness of diabetes-related complications are expected to drive steady growth in the 7MM diabetic neuropathy market from 2022 to 2036, creating significant commercial opportunities for both marketed therapies and emerging pipeline candidates.

Scope of the Diabetic Neuropathy Market Report

Coverage- 7MM
Diabetic Neuropathic Pain Companies- Novo Nordisk, Ionis Pharmaceuticals, Pfizer, Regeneron, NeuroMetrix, and others.
Diabetic Neuropathic Pain Therapies- Duloxetine, CNTX-6016, MEDI 7352, and others.
Diabetic Neuropathy Market Dynamics: Diabetic Neuropathy Market Drivers and Barriers
Diabetic Neuropathy Market Access and Reimbursement, Unmet Needs and Future Perspectives

Unlock Strategic Insights with DelveInsight’s Comprehensive Diabetic Neuropathy Market Report @ Diabetic Neuropathy Market Drivers and Barriers

Table of Content

1. Key Insights

2. Report Introduction

3. Diabetic Neuropathy Market Overview at a Glance

4. Executive Summary of Diabetic Neuropathy

5. Epidemiology and Market Forecast Methodology

6. Key Events

7. Disease Background and Overview

8. Treatment and Management

9. Epidemiology and Patient Population of Diabetic Neuropathy in the 7MM

10. Patient Journey

11. Marketed Therapies

12. Emerging Therapies

13. Diabetic Neuropathy: 7MM Market Analysis

14. Unmet Needs

15. SWOT Analysis

16. KOL Views

17. Market Access and Reimbursement

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About Us

Type 1 Diabetes Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Eli Lilly and Company, Regor Pharma, AstraZeneca, Eccogene, Pfizer, Sciwind Bio

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Type 1 Diabetes pipeline constitutes 85+ key companies continuously working towards developing 100+ Type 1 Diabetes treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Type 1 Diabetes Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Type 1 Diabetes Market.

The Type 1 Diabetes Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Type 1 Diabetes Pipeline Report:

Companies across the globe are diligently working toward developing novel Type 1 Diabetes treatment therapies with a considerable amount of success over the years.
Type 1 Diabetes companies working in the treatment market are Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc., Altimmune, Inc., Novartis, Amgen, Neuraly, Inc., Carmot Therapeutics, Inc., Inventiva Pharma, Inversago Pharma Inc, Applied Therapeutics, Inc., and others, are developing therapies for the Type 1 Diabetes treatment

Emerging Type 1 Diabetes therapies in the different phases of clinical trials are- Tirzepatide/LY3298176, Danuglipron, RGT001-075, AZD0186, ECC5004, PF-07081532, XW014, MN-001, SPI-62, HTD1801, Semaglutide, BMF-219, ALT-801, MBL949, LY3457263, AMG 133, DD01, CT-868, IVA337, INV-202, AT-001, and others are expected to have a significant impact on the Type 1 Diabetes market in the coming years.
In June 2026, The FDA has granted accelerated approval to teplizumab-mzwv (Tzield; Sanofi) for delaying the loss of insulin-producing function in children and adolescents aged 8 to 17 years who have been recently diagnosed with stage 3 type 1 diabetes. This approval expands the use of the anti-CD3 monoclonal antibody into the new-onset disease setting for pediatric patients. Announced on June 15, 2026, following approval on June 12, 2026, the decision establishes Tzield as the first FDA-approved disease-modifying therapy for children and adolescents with this stage 3 type 1 diabetes indication.
In June 2026, After reviewing Sanofi’s application to broaden the use of Tzield for type 1 diabetes and granting it priority consideration under an accelerated regulatory pathway, the FDA approved the expanded indication, although the decision came nearly two months after the initially expected action date. The accelerated approval permits children and adolescents aged 8 to 17 years who have been recently diagnosed with stage 3 type 1 diabetes to use Tzield to help preserve insulin-producing function by delaying the decline of endogenous insulin production. The monoclonal antibody originally received FDA approval in 2022 to delay the progression to stage 3 type 1 diabetes in individuals with stage 2 disease, making this latest approval a significant expansion of its clinical use.
In January 2026, The European Commission’s ruling positioned the therapy as the first disease-modifying option available for this condition in Europe. Teizeild (teplizumab) has received EU approval as the first treatment shown to modify the course of type 1 diabetes, with authorization to delay progression to stage 3 disease in patients aged eight years and older who are diagnosed with stage 2 T1D.
In December 2025, Data from the Insulin in Type 1 Diabetes Managed with Metformin (INTIMET) study showed that metformin did not improve insulin resistance in the liver, muscle, or adipose tissue after 26 weeks of treatment in patients with type 1 diabetes (T1D). Metformin, a widely used, safe, and cost-effective oral medication, is a first-line therapy for type 2 diabetes. Previous research has shown that metformin can modulate glucose metabolism in the liver and muscle in type 2 diabetes patients, as evidenced by hyperinsulinemic-euglycemic clamp studies.
In December 2025, SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company focused on developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune conditions, announced that it will deliver multiple oral presentations at the 2nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-Asia), taking place December 9–11, 2025, in Singapore.
In December 2025, New research suggests that a genetic test predicting the highest risk of developing type 1 diabetes could eventually be used in large-scale health studies to identify adults who may benefit from emerging therapies. This test, called a genetic risk score, evaluates a person’s entire genetic profile to estimate their likelihood of developing type 1 diabetes. The score is integrated into an online clinical calculator, developed by the University of Exeter team and now accessible to clinicians, which helps identify children at high risk. By entering routine clinical data—such as age, family history, blood test results, and the genetic risk score—clinicians can generate a personalized risk estimate.
In June 2025, Vertex Pharmaceuticals has shared the results from the Phase I/II segment of the Phase I/II/III FORWARD-101 trial, which is evaluating the stem cell-based, fully differentiated islet cell therapy, zimislecel (VX-880), in individuals with type 1 diabetes (T1D). The trial focuses on patients who suffer from severe hypoglycemic events (SHEs) and diminished hypoglycemia awareness. These results were presented at the American Diabetes Association (ADA) annual meeting in Chicago, USA.
In March 2025, Although drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are currently approved only for type 2 diabetes, emerging studies suggest they may also offer benefits for people with type 1 diabetes. Recent research on tirzepatide for type 1 diabetes was presented at the ATTD 2025 conference in Amsterdam. The study involved 84 overweight or obese adults with type 1 diabetes who received off-label tirzepatide. After 21 months, participants experienced an average weight loss of 23% along with sustained improvements in glucose control.

Type 1 Diabetes Overview

Type 1 Diabetes (T1D) is a chronic autoimmune condition in which the body's immune system mistakenly attacks insulin-producing beta cells in the pancreas. This leads to little or no insulin production, resulting in high blood sugar levels. T1D is typically diagnosed in children and young adults but can occur at any age. Symptoms include frequent urination, excessive thirst, weight loss, and fatigue. Management involves lifelong insulin therapy, blood sugar monitoring, a healthy diet, and regular exercise. Unlike Type 2 Diabetes, T1D is not preventable and requires continuous medical care to prevent complications.

Get a Free Sample PDF Report to know more about Type 1 Diabetes Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/type-1-diabetes-pipeline-insight

Emerging Type 1 Diabetes Drugs Under Different Phases of Clinical Development Include:

Tirzepatide/LY3298176: Eli Lilly and Company
Danuglipron: Pfizer
RGT001-075: Regor Pharmaceuticals Inc.
AZD0186: AstraZeneca
ECC5004: Eccogene
PF-07081532: Pfizer
XW014: Sciwind Biosciences USA Co., Ltd.
MN-001: MediciNova
SPI-62: Sparrow Pharmaceuticals
HTD1801: HighTide Biopharma Pty Ltd
Semaglutide: Novo Nordisk A/S
BMF-219: Biomea Fusion Inc.
ALT-801: Altimmune, Inc.
MBL949: Novartis
LY3457263: Eli Lilly and Company
AMG 133: Amgen
DD01: Neuraly, Inc.
CT-868: Carmot Therapeutics, Inc.
IVA337: Inventiva Pharma
INV-202: Inversago Pharma Inc
AT-001: Applied Therapeutics, Inc.

Type 1 Diabetes Route of Administration

Type 1 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Type 1 Diabetes Molecule Type

Type 1 Diabetes Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Type 1 Diabetes Pipeline Therapeutics Assessment

Type 1 Diabetes Assessment by Product Type
Type 1 Diabetes By Stage and Product Type
Type 1 Diabetes Assessment by Route of Administration
Type 1 Diabetes By Stage and Route of Administration
Type 1 Diabetes Assessment by Molecule Type
Type 1 Diabetes by Stage and Molecule Type

DelveInsight's Type 1 Diabetes Report covers around 100+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Type 1 Diabetes product details are provided in the report. Download the Type 1 Diabetes pipeline report to learn more about the emerging Type 1 Diabetes therapies

Some of the key companies in the Type 1 Diabetes Therapeutics Market include:

Key companies developing therapies for Type 1 Diabetes are - Eli Lilly, Merck, Novo Nordisk, Sanofi, AstraZeneca, Astellas Pharma, Boehringer Ingelheim GmbH, Novartis, and others.

Type 1 Diabetes Pipeline Analysis:

The Type 1 Diabetes pipeline report provides

The report provides detailed insights about companies that are developing therapies for the treatment of Type 1 Diabetes with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Type 1 Diabetes Treatment.
Type 1 Diabetes key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Type 1 Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Type 1 Diabetes market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Type 1 Diabetes drugs and therapies

Type 1 Diabetes Pipeline Market Drivers

Advancements in Gene and Cell Therapies, Rising Prevalence of Type 1 Diabetes, Regulatory Support and Fast-track Approvals, Growing Investment in Diabetes Research, Development of Novel Insulin Delivery Systems, Strategic Collaborations and Partnerships, are some of the important factors that are fueling the Type 1 Diabetes Market.

Type 1 Diabetes Pipeline Market Barriers

However, High Cost of Drug Development, Stringent Regulatory Requirements, Limited Awareness in Emerging Markets, Challenges in Beta-Cell Replacement Therapy, Limited Commercial Viability of Advanced Therapies, Adverse Drug Reactions and Safety Concerns, and other factors are creating obstacles in the Type 1 Diabetes Market growth.

Scope of Type 1 Diabetes Pipeline Drug Insight

Coverage: Global
Key Type 1 Diabetes Companies: Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc., Altimmune, Inc., Novartis, Amgen, Neuraly, Inc., Carmot Therapeutics, Inc., Inventiva Pharma, Inversago Pharma Inc, Applied Therapeutics, Inc., and others
Key Type 1 Diabetes Therapies: Tirzepatide/LY3298176, Danuglipron, RGT001-075, AZD0186, ECC5004, PF-07081532, XW014, MN-001, SPI-62, HTD1801, Semaglutide, BMF-219, ALT-801, MBL949, LY3457263, AMG 133, DD01, CT-868, IVA337, INV-202, AT-001, and others
Type 1 Diabetes Therapeutic Assessment: Type 1 Diabetes current marketed and Type 1 Diabetes emerging therapies
Type 1 Diabetes Market Dynamics: Type 1 Diabetes market drivers and Type 1 Diabetes market barriers

Request for Sample PDF Report for Type 1 Diabetes Pipeline Assessment and clinical trials

Table of Contents

1. Type 1 Diabetes Report Introduction

2. Type 1 Diabetes Executive Summary

3. Type 1 Diabetes Overview

4. Type 1 Diabetes- Analytical Perspective In-depth Commercial Assessment

5. Type 1 Diabetes Pipeline Therapeutics

6. Type 1 Diabetes Late Stage Products (Phase II/III)

7. Type 1 Diabetes Mid Stage Products (Phase II)

8. Type 1 Diabetes Early Stage Products (Phase I)

9. Type 1 Diabetes Preclinical Stage Products

10. Type 1 Diabetes Therapeutics Assessment

11. Type 1 Diabetes Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Type 1 Diabetes Key Companies

14. Type 1 Diabetes Key Products

15. Type 1 Diabetes Unmet Needs

16 . Type 1 Diabetes Market Drivers and Barriers

17. Type 1 Diabetes Future Perspectives and Conclusion

18. Type 1 Diabetes Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Aortic Aneurysm Stent Grafts Market to Grow at a CAGR of 5.71% Through 2030, Driven by Rising Aneurysm Prevalence and Advancements in Endovascular Repair Technologies

The Aortic Aneurysm Stent Grafts Market is witnessing significant growth owing to the increasing burden of vascular diseases, rising geriatric population, growing preference for minimally invasive aneurysm repair procedures, and continuous technological advancements in stent graft systems. Leading companies including Medtronic, Terumo, Cook Medical, Endologix, W. L. Gore & Associates, and Endospan are actively advancing innovative solutions to improve patient outcomes and expand treatment accessibility.

DelveInsight's latest market intelligence report, "Aortic Aneurysm Stent Grafts Market Insight, Competitive Landscape and Market Forecast, 2030," highlights the evolving landscape of endovascular aneurysm repair technologies and forecasts sustained market growth through 2030. The global Aortic Aneurysm Stent Grafts Market is projected to expand at a CAGR of 5.71% during the forecast period from 2024 to 2030.

The market growth is primarily fueled by the increasing prevalence of abdominal and thoracic aortic aneurysms, growing incidence of diabetes and cardiovascular disorders, favorable reimbursement policies, and rising adoption of minimally invasive procedures such as Endovascular Aneurysm Repair (EVAR) and Thoracic Endovascular Aortic Repair (TEVAR).

Discover comprehensive Aortic Aneurysm Stent Grafts market forecasts, competitive intelligence, and emerging technology trends

Increasing Burden of Vascular Aortic Aneurysm Stent Grafts Driving Market Expansion

Aortic aneurysms remain a major cardiovascular health concern globally, particularly among aging populations and patients with diabetes, hypertension, obesity, and atherosclerosis. According to the International Diabetes Federation, approximately 537 million adults were living with diabetes in 2021, a figure expected to rise substantially over the next two decades. The increasing prevalence of diabetes-associated vascular complications is contributing to the growing demand for advanced aneurysm management solutions, including stent graft systems.

The shift toward minimally invasive interventions has significantly transformed aneurysm treatment approaches. Compared with conventional open surgery, EVAR and TEVAR procedures offer reduced operative trauma, shorter hospital stays, and improved recovery outcomes, further strengthening adoption rates worldwide.

Want to understand how rising diabetes prevalence, aging demographics, and cardiovascular disease trends are influencing market demand? Access the full market assessment today.https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr

Aortic Aneurysm Stent Grafts Recent Development

Metastatic Prostate Cancer Market Size was ~USD 11,500 Million in 2025 and is Projected to Grow at a Significant CAGR Through 2036, Estimates DelveInsight

Leading Metastatic Prostate Cancer Therapies include Apalutamide (ERLEADA), Enzalutamide (XTANDI), Darolutamide (NUBEQA), Cabazitaxel (JEVTANA), Abiraterone acetate (ZYTIGA), Lutetium vipivotide tetraxetan (PLUVICTO), Olaparib (LYNPARZA), Talazoparib (TALZENNA), TLX591, Mevrometostat (PF-06821497), Cabozantinib (CABOMETYX), and others.

DelveInsight's Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of Metastatic Prostate Cancer, historical and forecasted epidemiology, and market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

To read more about the latest highlights related to the Metastatic Prostate Cancer Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/report-store/metastatic-prostate-cancer-market

Key Takeaways from the Metastatic Prostate Cancer Market Report

In March 2026, the Prostate Cancer Foundation introduced the Hastens-PCF Global Health Award to improve equitable access to prostate cancer detection, diagnosis, and treatment in emerging countries and to help expand the STAMPEDE2 clinical trial in Nigeria.
In December 2025, Telix Pharmaceuticals announced that the first patient has been dosed in Part 2 of its ProstACT Global Phase III study evaluating TLX591, its lead prostate cancer therapy candidate, in patients with metastatic castration-resistant prostate cancer (mCRPC).
The Metastatic Prostate Cancer Market Size was approximately USD 11,500 million across the 7MM (the US, EU4, the UK, and Japan) in 2025, and is projected to grow at a significant CAGR during the forecast period from 2026 to 2036.
The United States remains the largest Metastatic Prostate Cancer market, accounting for the highest revenue share in 2025, driven by high disease prevalence, strong uptake of novel therapies, advanced diagnostic infrastructure including PSMA PET/CT, and favorable reimbursement compared with EU4, the UK, and Japan.
According to DelveInsight's estimates, the total number of prevalent cases of metastatic prostate cancer in the 7MM were approximately 315,000 in 2025, with the US alone accounting for approximately 3,864,000 prevalent cases of prostate cancer overall.
Leading Metastatic Prostate Cancer companies include Curium, Bristol-Myers Squibb, Merck and Orion, Pfizer, Merus, Zenith Epigenetics, AstraZeneca, Telix International, Novartis, Eli Lilly/POINT Biopharma, and others.
Leading Metastatic Prostate Cancer Therapies includeApalutamide (ERLEADA), Enzalutamide (XTANDI), Darolutamide (NUBEQA), Cabazitaxel (JEVTANA), Abiraterone acetate (ZYTIGA), Lutetium vipivotide tetraxetan (PLUVICTO), Olaparib (LYNPARZA), Talazoparib (TALZENNA), TLX591, Mevrometostat (PF-06821497), Cabozantinib (CABOMETYX), and others.

To know more about why the United States is leading the market growth in the Metastatic Prostate Cancer Market, get a snapshot @ Metastatic Prostate Cancer Market Outlook

Metastatic Prostate Cancer Market Dynamics

The Metastatic Prostate Cancer therapeutics market is undergoing a major transition from conventional androgen deprivation therapy (ADT) toward combination-based, biomarker-driven, and precision-targeted treatment approaches. Metastatic prostate cancer is an advanced stage of prostate malignancy in which cancer cells spread beyond the prostate gland to distant sites — most commonly the bone, lymph nodes, liver, and lungs — progressing from localized disease through metastatic hormone-sensitive prostate cancer (mHSPC) and eventually to metastatic castration-resistant prostate cancer (mCRPC). The disease is diagnosed using a combination of PSA testing, bone scans, CT/MRI, PSMA PET/CT, and histopathological confirmation. While AR pathway inhibitors including enzalutamide (XTANDI), apalutamide (ERLEADA), darolutamide (NUBEQA), and abiraterone acetate (ZYTIGA) continue to dominate across mHSPC and mCRPC settings, the emergence of PARP inhibitors for HRR/BRCA-mutated disease and PSMA-targeted radioligand therapies such as Lu-177–PSMA-617 (PLUVICTO) is significantly reshaping the treatment paradigm. The rapidly ageing global population, rising prevalence of prostate cancer, expanding label approvals, integration of molecular testing and PSMA imaging, and a robust late-stage pipeline comprising next-generation PARP inhibitors, AKT inhibitors, PSMA-targeted agents, and novel AR degraders are collectively driving sustained market expansion through 2036.

Metastatic Prostate Cancer Market Segmentation Analysis

Metastatic Prostate Cancer Market by Disease Type (Metastatic Hormone-Sensitive Prostate Cancer — mHSPC/mCSPC, and Metastatic Castration-Resistant Prostate Cancer — mCRPC), Metastatic Prostate Cancer Market by Drug Class (Androgen Receptor Pathway Inhibitors — ARPIs, Androgen Deprivation Therapy — ADT, Chemotherapy, PARP Inhibitors, Radioligand Therapies, Immunotherapy, and Targeted Therapies), Metastatic Prostate Cancer Market by Biomarker Status (HRR/BRCA-Mutated, PSMA-Positive, MSI-High/dMMR, and Unselected), Metastatic Prostate Cancer Market by Line of Therapy (First-Line, Second-Line, and Later Lines), and Metastatic Prostate Cancer Market by Geography (North America — US; Europe — Germany, France, Italy, Spain, UK; Asia-Pacific — Japan)

Get a sneak peek at the Metastatic Prostate Cancer Market Dynamics @ Metastatic Prostate Cancer Market Dynamics Analysis

Metastatic Prostate Cancer Companies

Curium, Bristol-Myers Squibb, Merck and Orion, Pfizer, Merus, Zenith Epigenetics, AstraZeneca, Telix International, Novartis, Eli Lilly/POINT Biopharma, Johnson & Johnson, Astellas Pharma, Exelixis, Ipsen Pharma, Takeda, Xencor, ORIC Pharmaceuticals, Blue Earth Therapeutics, Promontory Therapeutics, and others.

Metastatic Prostate Cancer Market Drivers

The Metastatic Prostate Cancer Market is poised for significant growth, driven by the high and rising global burden of prostate cancer — particularly in the rapidly ageing population — and the substantial progression of patients to advanced metastatic stages where unmet need remains greatest. The expanding adoption of treatment intensification strategies combining ADT with ARPIs and chemotherapy, supported by pivotal trials including TITAN, ARCHES, ARASENS, and PEACE-1, is improving survival outcomes and driving earlier use of combination regimens. The establishment of theragnostics as a new treatment pillar through PLUVICTO, rapid growth in genomically targeted PARP inhibitor therapies for HRR/BRCA-mutated mCRPC, increasing integration of PSMA PET imaging and molecular biomarker testing, and a robust late-stage pipeline including next-generation radioligand therapies, EZH2 inhibitors, and novel AR degraders are further accelerating market expansion. Favorable reimbursement in the US, evolving treatment guidelines, and growing precision oncology adoption across the 7MM collectively position the Metastatic Prostate Cancer Market for strong growth from 2026 to 2036.

Which key players in the Metastatic Prostate Cancer Market are set to emerge as trendsetters? Explore @ Metastatic Prostate Cancer Companies

Scope of the Metastatic Prostate Cancer Market Report

Coverage: 7MM
Study Period: 2022–2036
Forecast Period: 2026–2036
Metastatic Prostate Cancer Companies: Curium, Bristol-Myers Squibb, Merck and Orion, Pfizer, Merus, Zenith Epigenetics, AstraZeneca, Telix International, Novartis, Eli Lilly/POINT Biopharma, and others.
Metastatic Prostate Cancer Therapies: Apalutamide (ERLEADA), Enzalutamide (XTANDI), Darolutamide (NUBEQA), Cabazitaxel (JEVTANA), Abiraterone acetate (ZYTIGA), Lutetium vipivotide tetraxetan (PLUVICTO), Olaparib (LYNPARZA), Talazoparib (TALZENNA), TLX591, Mevrometostat (PF-06821497), Cabozantinib (CABOMETYX), and others.
Key Analysis: Total Market Size, Market Size by Therapies and Drug Class, Epidemiology Segmentation, Pipeline Analysis (Phase I–III), Drug Uptake, Reimbursement, SWOT and Conjoint Analysis, KOL Views

Interested in knowing the Metastatic Prostate Cancer Market outlook through 2036? Click to get a snapshot of the Metastatic Prostate Cancer Market Trends

Table of Contents

Key Insights
Report Introduction
Executive Summary of Metastatic Prostate Cancer
Key Events
Epidemiology and Market Forecast Methodology
Prostate Cancer Market Overview at a Glance
Disease Background and Overview
Epidemiology and Patient Population
Patient Journey
Marketed Drugs
Additional Marketed Therapies
Emerging Drugs
Metastatic Prostate Cancer: 7MM Analysis
Unmet Needs
SWOT Analysis
KOL Views
Market Access and Reimbursement
Appendix
DelveInsight Capabilities
Disclaimer

About Us

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-prostate-cancer-market

Coronary Microvascular Dysfunction Market is Anticipated to Witness Significant Growth by 2034, Driven by Rising Disease Awareness, Advancements in Diagnostics, and Emerging Therapeutic Opportunities

The Coronary Microvascular Dysfunction Market is growing steadily due to rising awareness, improved diagnostics, and increasing recognition of CMD in ischemic heart disease. Advanced tools such as CMR, PET, invasive coronary assessment, and technologies like the CoroFlow Cardiovascular System are improving diagnosis and supporting research into innovative treatments, driving market growth through 2034.

DelveInsight, a leading market research and consulting company, announces the release of its latest report, “Coronary Microvascular Dysfunction (CMD) Market Insights, Epidemiology, and Market Forecast–2034.” The report provides a comprehensive understanding of Coronary Microvascular Dysfunction, including historical and forecasted epidemiology, diagnostic and treatment landscape, market trends, market size, market share, unmet needs, competitive dynamics, and future opportunities across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Key Takeaways from the Coronary Microvascular Dysfunction Market

The Coronary Microvascular Dysfunction market size is anticipated to increase throughout the forecast period 2020–2034.
The growth of the CMD market is expected to be driven by increasing diagnosed prevalence, advancements in diagnostic technologies, rising awareness, and the potential launch of emerging therapies.
Coronary Microvascular Dysfunction affects approximately 30% of individuals diagnosed with angina, while nearly 50% of patients with non-obstructive coronary artery disease (NOCAD) exhibit evidence of CMD.
Research suggests that women experience a higher prevalence of both NOCAD and CMD compared to men.
According to DelveInsight estimates, the United States accounted for nearly 50% of total CMD cases in the 7MM, while EU4 and the United Kingdom represented approximately 30%, and Japan accounted for 20%.
In 2025, the United States reported approximately 1.13 million prevalent CMD cases, which are expected to increase during the forecast period.
Among gender-specific cases in the United States, females represented the majority of the CMD patient population.
The total CMD market size across the 7MM was approximately USD 732 million in 2020 and is projected to reach nearly USD 837 million by 2034.
The United States represented the largest Coronary Microvascular Dysfunction market, reaching approximately USD 257 million in 2025, and is expected to exceed USD 317 million by 2034.
There are currently no US FDA-approved therapies specifically indicated for Coronary Microvascular Dysfunction, highlighting a significant unmet need and future commercial opportunity.

Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/coronary-microvascular-dysfunction-market

Key Factors Driving the Coronary Microvascular Dysfunction Market

Rising Disease Awareness and Recognition

Growing awareness among healthcare professionals regarding the role of coronary microvascular dysfunction in ischemic heart disease has resulted in increased diagnosis and improved patient identification. CMD is increasingly recognized as an important contributor to angina and myocardial ischemia in patients without obstructive coronary artery disease.

Advancements in Diagnostic Technologies

The adoption of advanced imaging technologies such as PET, CMR imaging, coronary flow reserve assessment, invasive coronary function testing, and physiological measurement systems is significantly improving diagnostic accuracy and expanding the diagnostic market.

Growing Burden of Cardiovascular Disease

The increasing prevalence of cardiovascular risk factors, including hypertension, diabetes, obesity, smoking, and metabolic disorders, is contributing to a growing burden of CMD and expanding the addressable patient population.

Increasing Research into Novel Therapeutic Approaches

Ongoing research evaluating therapies such as aminophylline, fasudil, ACE inhibitors, antianginal agents, and other investigational treatments is expected to improve future treatment outcomes and support market growth.

Coronary Microvascular Dysfunction Competitive Landscape

Currently, there are no approved therapies specifically indicated for Coronary Microvascular Dysfunction. Treatment primarily focuses on symptom management, cardiovascular risk factor modification, and improving endothelial function. Commonly used therapies include Ranolazine, Beta-blockers, ACE Inhibitors, Calcium Channel Blockers (CCBs), Nitrates, and Metformin, alongside lifestyle interventions and cardiac rehabilitation programs.

The emerging Coronary Microvascular Dysfunction treatment landscape remains relatively underdeveloped but presents significant opportunities for innovation. Investigational approaches including Aminophylline, Fasudil, and other therapies targeting microvascular dysfunction, endothelial impairment, and abnormal coronary vasoreactivity are being explored to address substantial unmet clinical needs.

On the diagnostic side, technologies such as the CoroFlow Cardiovascular System, advanced PET imaging, Cardiac MRI, and invasive coronary physiological assessments are playing increasingly important roles in improving diagnostic accuracy and patient stratification.

Discover more about therapies set to grab major Coronary Microvascular Dysfunction market share @ Coronary Microvascular Dysfunction Treatment Landscape.

Recent Developments in the Coronary Microvascular Dysfunction Market

Increasing adoption of coronary flow reserve (CFR) assessment is improving identification of CMD in patients with angina and non-obstructive coronary artery disease.
Cardiac Magnetic Resonance Imaging (CMR) is increasingly emerging as a preferred non-invasive diagnostic approach for evaluating CMD.
The CoroFlow Cardiovascular System continues to expand utilization for physiological assessment of coronary microcirculation through measurements of CFR and IMR.
Research investigating aminophylline, fasudil, and other novel pharmacologic interventions is ongoing to address significant unmet therapeutic needs in CMD patients.

What is Coronary Microvascular Dysfunction?

Coronary Microvascular Dysfunction (CMD) is a cardiovascular disorder characterized by structural and functional abnormalities of the small coronary blood vessels that regulate myocardial blood flow. These abnormalities lead to impaired vasodilation, increased coronary microvascular resistance, and abnormal vasoconstrictive responses, resulting in myocardial ischemia despite the absence of significant blockages in major coronary arteries. Patients often experience prolonged chest pain, shortness of breath, fatigue, reduced exercise tolerance, and diminished quality of life.

Coronary Microvascular Dysfunction Epidemiology Segmentation

The Coronary Microvascular Dysfunction epidemiology section provides insights into historical and forecasted patient populations and includes:

Total Prevalent Cases of Angina
Total Prevalent Cases of Angina with No Large Vessel CAD
Total Prevalent Cases of Coronary Microvascular Dysfunction
Gender-specific Cases of Coronary Microvascular Dysfunction
Treated Cases of Coronary Microvascular Dysfunction
Country-specific CMD Patient Population
Forecasted Epidemiology Trends Across the 7MM

Scope of the Coronary Microvascular Dysfunction Market Report

Therapeutic Assessment: Current and Emerging Coronary Microvascular Dysfunction Therapies
Diagnostic Assessment: Current and Emerging Diagnostic Modalities
Coronary Microvascular Dysfunction Market Dynamics: Drivers, Barriers, Opportunities, and Future Trends
Key Diagnostic Technologies: PET, Cardiac MRI, Coronary Flow Reserve Assessment, CoroFlow Cardiovascular System, and others
Key Therapies: Ranolazine, ACE Inhibitors, Beta-blockers, Calcium Channel Blockers, Aminophylline, Fasudil, and others
Competitive Intelligence Analysis: SWOT Analysis and Market Entry Strategies
Coronary Microvascular Dysfunction Market Size, Market Share, Treatment Trends, and Industry Outlook
KOL Perspectives, Analyst Views, Market Access, and Reimbursement Assessment

To know more about Coronary Microvascular Dysfunction companies working in the treatment market, visit @ Coronary Microvascular Dysfunction Clinical Trials and Therapeutic AssessmentTable of Contents

Coronary Microvascular Dysfunction Market Report Introduction
Executive Summary for Coronary Microvascular Dysfunction
SWOT Analysis of Coronary Microvascular Dysfunction
Coronary Microvascular Dysfunction Patient Share (%) Overview at a Glance
Coronary Microvascular Dysfunction Market Overview at a Glance
Coronary Microvascular Dysfunction Disease Background and Overview
Coronary Microvascular Dysfunction Epidemiology and Patient Population
Country-Specific Patient Population of Coronary Microvascular Dysfunction
Diagnostic Competitive Landscape
Current Diagnostic Approaches
Emerging Diagnostic Modalities
Current Treatment and Medical Practices
Coronary Microvascular Dysfunction Unmet Needs
Coronary Microvascular Dysfunction Emerging Therapies
Coronary Microvascular Dysfunction Market Outlook
Country-Wise Coronary Microvascular Dysfunction Market Analysis (2020–2034)
Coronary Microvascular Dysfunction Market Access and Reimbursement
Coronary Microvascular Dysfunction Market Drivers
Coronary Microvascular Dysfunction Market Barriers
KOL Perspectives
SWOT Analysis
Appendix
Coronary Microvascular Dysfunction Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through its subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

PROTAC Market is Expected to Reach USD 16 Billion by 2036, Driven by the Emergence of Targeted Protein Degradation Therapies and Expanding Oncology Applications | DelveInsight

The PROTAC Market is witnessing remarkable growth driven by advancements in targeted protein degradation technologies, increasing focus on previously undruggable targets, rising investments in oncology drug development, and growing adoption of precision medicine approaches. The anticipated launch of emerging therapies such as Vepdegestrant, Luxdegalutamide, ASP3082, DT2216, and others is expected to significantly transform the PROTAC drug market and accelerate market expansion through 2036.

DelveInsight, a leading market research and consulting company, announces the release of its latest report, “PROTAC Market Size, Target Population, Competitive Landscape & Market Forecast – 2036.” The report provides a comprehensive understanding of the PROTAC market, including target patient population analysis, emerging therapies, competitive landscape, market trends, market size, market share, technology assessment, pricing dynamics, and future opportunities across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Key Takeaways from the PROTAC Market

The PROTAC market is expected to witness substantial growth during the forecast period 2022–2036.
The total PROTAC market size is projected to increase from approximately USD 10 billion in 2028 to nearly USD 16 billion by 2036.
PROTACs represent one of the most promising targeted protein degradation technologies, offering the ability to degrade disease-causing proteins rather than simply inhibiting them.
In 2019, Bavdegalutamide (ARV-110) became the first PROTAC molecule to enter clinical development, establishing clinical proof-of-concept for the modality.
Key indications driving the PROTAC market include HR+/HER2− Breast Cancer, Triple Negative Breast Cancer (TNBC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Colorectal Cancer, and Non-Small Cell Lung Cancer (NSCLC).
In 2025, the United States reported approximately 215,000 incident cases of HR+/HER2− Breast Cancer, 47,000 incident TNBC cases, 54,000 prevalent mCRPC cases, 154,000 incident colorectal cancer cases, and 207,000 incident NSCLC cases, representing significant addressable populations for PROTAC therapies.
Leading PROTAC companies include Arvinas, Pfizer, Novartis, Astellas Pharma, and Dialectic Therapeutics, among others.
Key emerging PROTAC therapies include Vepdegestrant (ARV-471), Luxdegalutamide (ARV-766), ASP3082, and DT2216.

Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/protac-market-forecast

Key Factors Driving the PROTAC Market

Rising Interest in Targeted Protein Degradation

PROTACs are revolutionizing drug development by enabling selective degradation of disease-causing proteins rather than conventional inhibition. This approach provides opportunities to target proteins previously considered undruggable, expanding therapeutic possibilities across multiple disease areas.

Expanding Applications in Oncology

The majority of clinical-stage PROTACs are being developed for oncology indications, particularly breast cancer, prostate cancer, colorectal cancer, and lung cancer. Growing cancer incidence and demand for precision therapies continue to support market expansion.

Ability to Overcome Drug Resistance

One of the major advantages of PROTAC technology is its potential to overcome resistance mechanisms associated with conventional therapies by degrading the target protein rather than simply blocking its activity.

Increasing Strategic Collaborations

Major partnerships such as Arvinas-Pfizer and Arvinas-Novartis demonstrate growing pharmaceutical industry confidence in PROTAC technology and are accelerating development and commercialization activities.

PROTAC Competitive Landscape

Several PROTAC therapies are advancing through clinical development, with oncology remaining the primary focus area. Leading companies including Arvinas, Pfizer, Novartis, Astellas Pharma, and Dialectic Therapeutics are actively developing innovative targeted protein degraders across multiple cancer indications.

The most advanced PROTAC candidates include Vepdegestrant (ARV-471), Luxdegalutamide (ARV-766), ASP3082, and DT2216. These therapies target diverse proteins including estrogen receptor (ER), androgen receptor (AR), and KRAS G12D, aiming to improve efficacy, overcome resistance mechanisms, and expand treatment options for patients with difficult-to-treat cancers.

Discover more about therapies set to grab major PROTAC market share @ PROTAC Clinical Trials and Therapeutic Assessment.

Recent Developments in the PROTAC Market

In October 2025, Arvinas announced new patient-reported outcomes data from the Phase III VERITAC-2 trial evaluating Vepdegestrant, presented at the 2025 ESMO Congress.
In November 2025, Arvinas presented multiple Vepdegestrant-related abstracts at the San Antonio Breast Cancer Symposium (SABCS).
In March 2025, Arvinas and Pfizer reported positive topline results from the Phase III VERITAC-2 study, demonstrating significant progression-free survival improvement in ESR1-mutant breast cancer patients.
In September 2024, Astellas Pharma reported encouraging preliminary safety and efficacy data for ASP3082 in advanced pancreatic cancer, colorectal cancer, and NSCLC patients carrying KRAS G12D mutations.
In April 2024, Arvinas entered into an exclusive global licensing agreement with Novartis for the development and commercialization of Luxdegalutamide (ARV-766).

What are PROTACs?

Proteolysis Targeting Chimeras (PROTACs) are bifunctional small molecules designed to selectively degrade disease-causing proteins through the ubiquitin-proteasome system. A PROTAC molecule consists of a target protein ligand, a linker, and an E3 ligase ligand. Unlike traditional inhibitors that block protein function, PROTACs trigger complete degradation of the target protein, offering a potentially more durable therapeutic effect and expanding the range of druggable targets.

PROTAC Target Population Segmentation

The PROTAC market report evaluates target populations across major oncology indications, including:

HR+/HER2− Breast Cancer
Triple Negative Breast Cancer (TNBC)
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Colorectal Cancer (mCRC)
Non-Small Cell Lung Cancer (NSCLC)
Other Emerging Oncology Indications
Total Eligible Patient Pool for PROTAC Therapies
Total Treated Cases in Selected Indications

Scope of the PROTAC Market Report

Therapeutic Assessment: Emerging PROTAC Therapies
PROTAC Market Dynamics: Drivers, Barriers, Opportunities, and Future Trends
Key Companies: Arvinas, Pfizer, Novartis, Astellas Pharma, Dialectic Therapeutics, and others
Key Therapies: Vepdegestrant, Luxdegalutamide, ASP3082, DT2216, and others
Competitive Intelligence Analysis: SWOT Analysis and Market Entry Strategies
PROTAC Market Size, Market Share, Industry Trends, and Forecast Analysis
Technology Assessment and Innovation Landscape
Pricing Trends and Analogue Analysis
KOL Perspectives, Analyst Views, Market Access, and Reimbursement Assessment

To know more about PROTAC companies working in the treatment market, visit @ PROTAC Clinical Trials and Therapeutic AssessmentTable of Contents

PROTAC Market Report Introduction
Executive Summary for PROTAC
PROTAC Market Overview at a Glance
Technology Assessment of PROTAC Therapies
Target Population and Epidemiology Analysis
Total Eligible Patient Pool for PROTAC Therapies
Emerging PROTAC Therapies
Vepdegestrant (ARV-471): Arvinas and Pfizer
Luxdegalutamide (ARV-766): Arvinas and Novartis
ASP3082: Astellas Pharma
Competitive Landscape
Clinical Trial Analysis
Conjoint Analysis
Market Outlook
Country-wise PROTAC Market Analysis (2022–2036)
Market Size by Indication
Market Size by Therapy
Market Access and Reimbursement
Pricing Trends and Analogue Assessment
KOL Perspectives
SWOT Analysis
Unmet Needs
Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight

About DelveInsight